Peanut Allergy Oral Immunotherapy Desensitization
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Adverse effects
研究概览
简要总结
The purpose of the study is to determine how a type of treatment for peanut allergy known as oral desensitization works in the immune system.
Objectives
- To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure.
- To assess quality of life in peanut allergic subjects before and after desensitization.
- To compare serum metabolites in peanut allergic and non peanut allergic subjects.
详细描述
Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions, and the only treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidently ingest peanut. OIT has been shown to desensitize peanut allergic subjects (Hofmann et al. 2009). This would protect patients who have no other treatment, and may even form the basis for true tolerance to peanut in the future.
Objectives:
- To determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure.
- To assess quality of life in peanut allergic subjects before and after desensitization.
- To compare serum metabolites in peanut allergic and non peanut allergic subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 5 Years 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients must be between 5 and 10 years of age.
- •Patients will be confirmed to have peanut allergy based on a history of significant clinical symptoms within 60 minutes after the ingestion of peanut,the presence of specific IgE to peanut (a positive skin prick test to peanut, defined as a wheal 3 mm larger than that of the saline control; and a positive in vitro IgE [CAP-FEIA] result of >15 kU/L..
- •Patients will also be accepted into the study if they have a clinical reaction to peanut ingestion within the past 6 months, a positive skin prick test to peanut as defined previously, and an in vitro peanut IgE (CAP-FEIA) result of 7 kU/L or greater.
- •Subjects must be free of any clinically significant disease which may interfere with study evaluations.
排除标准
- •Use of antihistamines or decongestant therapy 7 days prior to the clinic visit. (antihistamines eg. diphenhydramine, desloratadine etc or throughout the desensitization phase of the study.
- •Patients who had an acute allergic reaction to food other than peanut, drugs, or stinging insects one month prior to the recruitment clinic visit
- •Patients who have had a respiratory infection one month prior to the recruitment clinic visit.
- •Patients with significant or uncontrolled asthma, (inhaled corticosteroids (fluticasone >500 mcg per day, ciclesonide >400 mcg per day or budesonide >800 mcg per day or the corresponding combination inhalers, oral prednisone in the preceding 1 month and FEV1 < 80% predicted). Nasal steroids, bronchodilators and leukotriene inhibitors will be permitted. If Prednisone is taken, it must also be stopped 1 month prior to blood being drawn if possible.
- •Patients who received allergy injections (immunotherapy) to environmental allergens at any time in the past. Symptomatic atopic dermatitis or chronic urticaria which may interfere with ability to evaluate oral immunotherapy and /or requiring daily medication including antihistamines.
- •Patients with problems related to compliance or following study instructions. Inability to come to hospital every 2 weeks for dose escalation.
研究组 & 干预措施
Oral Immunotherapy with placebo antihistamines
500 mg Peanut Protein with placebo antihistamines
干预措施: Peanut protein (Procedure)
Double Placebo
Placebo (Oat flour) and placebo antihistamines
干预措施: Oat flour (Procedure)
Oral Immunotherapy with H1 and H2 antihistamines
500 mg Peanut Protein with Dosage of desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) and ranitidine be 5ml (15mg/ml=75 mg) po bid.
干预措施: Peanut protein (Procedure)
Oral Immunotherapy with H1 and H2 antihistamines
500 mg Peanut Protein with Dosage of desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) and ranitidine be 5ml (15mg/ml=75 mg) po bid.
干预措施: Antihistamine (Drug)
结局指标
主要结局
Adverse effects
时间窗: 6-12 months
Frequency and risk of adverse events, overall and stratified by organ system and severity
次要结局
- Health related quality of life pre and post intervention(6-12 months)
- Eliciting doses to oral food challenge(6-12 months)
研究者
Dr. Susan Waserman
Professor
McMaster University